Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

J. S. Smolen; P. Emery; Gianfranco Ferraccioli; W. Samborski; F. Berenbaum; O. R. Davies; W. Koetse; O. Purcaru; B. Bennett; H. Burkhardt

doi:10.1136/annrheumdis-2013-204632

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

J. S. Smolen, P. Emery, Gianfranco Ferraccioli, W. Samborski, F. Berenbaum, O. R. Davies, W. Koetse, O. Purcaru, B. Bennett, H. Burkhardt

Risultato della ricerca: Contributo in rivista › Articolo in rivista

68 Citazioni (Scopus)

Abstract

This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.

Lingua originale	English
pagine (da-a)	N/A-N/A
Rivista	Annals of the Rheumatic Diseases
DOI	https://doi.org/10.1136/annrheumdis-2013-204632
Stato di pubblicazione	Pubblicato - 2014
Pubblicato esternamente	Sì

Keywords

Anti-TNF
DMARDs (biologic)
Disease Activity
Rheumatoid Arthritis

Accesso al documento

10.1136/annrheumdis-2013-204632

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Smolen, J. S., Emery, P., Ferraccioli, G., Samborski, W., Berenbaum, F., Davies, O. R., Koetse, W., Purcaru, O., Bennett, B., & Burkhardt, H. (2014). Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Annals of the Rheumatic Diseases, N/A-N/A. https://doi.org/10.1136/annrheumdis-2013-204632

@article{7bd33d63c0d24779a8767b380425c0a4,

title = "Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial",

abstract = "This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.",

keywords = "Anti-TNF, DMARDs (biologic), Disease Activity, Rheumatoid Arthritis, Anti-TNF, DMARDs (biologic), Disease Activity, Rheumatoid Arthritis",

author = "Smolen, {J. S.} and P. Emery and Gianfranco Ferraccioli and W. Samborski and F. Berenbaum and Davies, {O. R.} and W. Koetse and O. Purcaru and B. Bennett and H. Burkhardt",

year = "2014",

doi = "10.1136/annrheumdis-2013-204632",

language = "English",

pages = "N/A--N/A",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "London, United Kingdom: BMJ / British Medical Journal Publishing Group",

}

Smolen, JS, Emery, P, Ferraccioli, G, Samborski, W, Berenbaum, F, Davies, OR, Koetse, W, Purcaru, O, Bennett, B & Burkhardt, H 2014, 'Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial', Annals of the Rheumatic Diseases, pagg. N/A-N/A. https://doi.org/10.1136/annrheumdis-2013-204632

TY - JOUR

T1 - Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

AU - Smolen, J. S.

AU - Emery, P.

AU - Ferraccioli, Gianfranco

AU - Samborski, W.

AU - Berenbaum, F.

AU - Davies, O. R.

AU - Koetse, W.

AU - Purcaru, O.

AU - Bennett, B.

AU - Burkhardt, H.

PY - 2014

Y1 - 2014

N2 - This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.

AB - This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.

KW - Anti-TNF

KW - DMARDs (biologic)

KW - Disease Activity

KW - Rheumatoid Arthritis

KW - Anti-TNF

KW - DMARDs (biologic)

KW - Disease Activity

KW - Rheumatoid Arthritis

UR - http://hdl.handle.net/10807/64772

U2 - 10.1136/annrheumdis-2013-204632

DO - 10.1136/annrheumdis-2013-204632

M3 - Article

SN - 0003-4967

SP - N/A-N/A

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

ER -

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo